Genetic Engineering & Biotechnology
Concepts (14)
Biosafety ensures safe handling of biotech products, governed by protocols like Cartagena. Bioethics addresses moral dilemmas in life sciences, covering issues like biopiracy, genetic privacy, and the
Definition
Biosafety refers to the measures and protocols implemented to prevent adverse effects on human health and the environment from the handling, use, and release of biological agents, particularly Living Modified Organisms (LMOs) or Genetically Modified Organisms (GMOs), resulting from modern biotechnology. It aims to minimize risks associated with biotechnological research and its applications.
Bioethics is a field of study concerned with the ethical implications of biological and medical advances, particularly in areas like genetic engineering, cloning, human experimentation, and environmental impact. It seeks to establish moral principles and guidelines for responsible conduct in life sciences and healthcare, often guided by principles of autonomy, beneficence, non-maleficence, and justice.
Key Facts
- Cartagena Protocol on Biosafety: Adopted in Montreal on January 29, 2000, and entered into force on September 11, 2003. It is a supplementary agreement to the Convention on Biological Diversity (CBD).
- Objective of Cartagena Protocol: To ensure the safe handling, transport, and use of LMOs resulting from modern biotechnology that may have adverse effects on biological diversity, taking into account risks to human health.
- Advance Informed Agreement (AIA) Procedure: A key mechanism under the Cartagena Protocol requiring exporting countries to notify importing countries before the first intentional transboundary movement of LMOs for introduction into the environment.
- India's Status: India is a signatory and has ratified the Cartagena Protocol on Biosafety in 2003, demonstrating its commitment to biosafety regulations.
- Biosafety Levels (BSL): Laboratories are classified into four biosafety levels (BSL-1 to BSL-4) based on the risk associated with the biological agents being handled, with BSL-4 representing the highest containment for highly dangerous pathogens.
- Biopiracy: The unauthorized appropriation or commercial exploitation of traditional knowledge or biological resources, often without fair compensation to the indigenous communities or countries of origin. It often involves patenting traditional knowledge or genetic resources without prior informed consent.
- Brain Fingerprinting Technology: A controversial neuroscientific technique that measures brainwave responses (P300 wave) to detect if specific information is stored in a subject's memory. Its ethical implications include privacy, self-incrimination, and reliability in legal contexts.
Mechanism/Framework
International Biosafety Framework: The Cartagena Protocol on Biosafety is the cornerstone. It establishes procedures for LMO transboundary movement, risk assessment, risk management, and information sharing through the Biosafety Clearing-House (BCH).
National Biosafety Framework in India: India has a robust regulatory framework for biosafety, primarily governed by the Rules for the Manufacture, Use, Import, Export and Storage of Hazardous Microorganisms/Genetically Engineered Organisms or Cells, 1989, notified under the Environment (Protection) Act, 1986. Key bodies include:
- Ministry of Environment, Forest and Climate Change (MoEFCC): The nodal ministry.
- Genetic Engineering Appraisal Committee (GEAC): The apex body responsible for approval of activities involving large-scale use of hazardous microorganisms and recombinants in research and industrial production, and for approval of genetically engineered organisms and products for environmental release.
- Review Committee on Genetic Manipulation (RCGM): Under the Department of Biotechnology (DBT), it monitors ongoing research activities and approves experiments involving GMOs.
- Institutional Biosafety Committees (IBSCs): Established at the institutional level to ensure compliance with biosafety guidelines.
Exam Angle
For Prelims, focus on the names of protocols (Cartagena, Nagoya), their objectives, key mechanisms (AIA, BCH), India's ratification status, and the names of regulatory bodies (GEAC, RCGM). For Mains, the emphasis shifts to analytical aspects: the ethical dilemmas posed by genetic engineering, the challenges of regulating emerging technologies, the socio-economic implications of biopiracy, and the balance between innovation, safety, and ethical considerations. Essay questions often explore the governance of biotechnology, the precautionary principle, and the role of international cooperation in biosafety and bioethics.
scitech-diagram-Indian_Biosafety_Regulatory_Process
Analysis
Biosafety and bioethics are critical pillars in the governance of modern biotechnology, ensuring that scientific advancements serve humanity responsibly. The rapid pace of innovation in genetic engineering, synthetic biology, and neurotechnology necessitates a dynamic and robust regulatory and ethical framework.
Biosafety: Balancing Innovation and Precaution The core challenge in biosafety is to facilitate beneficial biotechnological applications while mitigating potential risks. LMOs, while offering solutions in agriculture (e.g., pest-resistant crops like Bt Cotton), medicine (e.g., insulin production), and industry, also pose ecological concerns. These include the potential for gene flow to wild relatives, the development of herbicide or insect resistance in target populations, and unforeseen impacts on non-target organisms. The precautionary principle, enshrined in Principle 15 of the Rio Declaration, often guides biosafety regulations, suggesting that where there are threats of serious or irreversible damage, lack of full scientific certainty shall not be used as a reason for postponing cost-effective measures to prevent environmental degradation. India's biosafety framework, with the GEAC at its helm, aims to strike this balance, evaluating each case for environmental release on a case-by-case basis. However, challenges remain in risk assessment methodologies, public perception, and the enforcement of post-release monitoring.
Bioethics: Navigating the Moral Landscape of Life Sciences Bioethics grapples with profound questions about human dignity, justice, and the very definition of life.
- Genetic Engineering and Human Germline Editing: Technologies like CRISPR-Cas9 have revolutionized gene editing, offering therapeutic potential for genetic diseases. However, the prospect of human germline editing (altering genes in sperm, eggs, or embryos, which would be heritable) raises significant ethical concerns about 'designer babies,' unintended consequences for future generations, and exacerbating social inequalities. Most international guidelines and national policies currently prohibit or strongly discourage germline editing, advocating for somatic gene therapy (non-heritable changes) for therapeutic purposes.
- Biopiracy and Traditional Knowledge: Biopiracy highlights the ethical imperative of justice and respect for indigenous communities. The commercial exploitation of traditional knowledge and biological resources without equitable benefit sharing undermines the rights of knowledge holders. The Nagoya Protocol on Access and Benefit-sharing (ABS), a supplementary agreement to the CBD, aims to address this by establishing a legal framework for fair and equitable sharing of benefits arising from the utilization of genetic resources. India's Biological Diversity Act, 2002, and the Traditional Knowledge Digital Library (TKDL) are proactive steps to prevent biopiracy by documenting traditional knowledge and making it accessible to patent offices globally, thus preventing erroneous patent grants. The reference material's discussion on IPRs and Geographical Indications is relevant here, as biopiracy often involves attempts to secure IPRs over traditional knowledge.
- Brain Fingerprinting Technology: This technology raises concerns about mental privacy and the right against self-incrimination (Article 20(3) of the Indian Constitution). While proponents argue its potential in criminal investigations, critics highlight its unreliability, the potential for coercion, and the ethical implications of 'reading minds.' The Supreme Court of India, in Selvi & Ors vs. State of Karnataka (2010), ruled that narco-analysis, polygraphy, and brain electrical activation profile (BEAP) tests (which includes brain fingerprinting) are involuntary and violate Article 20(3) if conducted without consent.
Comparison Table
| Feature | Biosafety | Bioethics |
|---|---|---|
| Primary Focus | Preventing physical harm to health & environment from biotech. | Moral principles and values in life sciences & medicine. |
| Key Questions | Is it safe? What are the risks? How to manage them? | Is it right? Should we do it? What are the moral implications? |
| Regulatory Tools | Protocols (Cartagena), guidelines, risk assessment, containment levels. | Ethical guidelines, codes of conduct, institutional ethics committees, public debate. |
| Scope | Primarily LMOs/GMOs, hazardous biological agents, lab practices. | Broader: genetic engineering, human cloning, organ donation, end-of-life care, biopiracy, neuroethics. |
| Underlying Principle | Precautionary Principle, risk management. | Autonomy, Beneficence, Non-maleficence, Justice. |
Case Study: Bt Cotton in India
Bt Cotton, genetically modified with a gene from the bacterium Bacillus thuringiensis to produce an insecticidal protein, was introduced in India in 2002. Its adoption led to significant increases in cotton yields and reduced pesticide use, benefiting millions of farmers. However, its introduction was not without biosafety and bioethical debates:
- Biosafety Concerns: Initial concerns included potential impacts on non-target insects, development of pest resistance (e.g., pink bollworm resistance), and gene flow to wild cotton varieties. While GEAC approved its commercial release after extensive trials, ongoing monitoring and stewardship are crucial.
- Bioethical Concerns: Debates centered on seed monopolies (Mahyco-Monsanto), intellectual property rights, farmers' access to affordable seeds, and the long-term sustainability of GM crops. The issue of farmers' rights and benefit sharing with traditional breeders, as envisioned in the Protection of Plant Varieties and Farmers' Rights Act, 2001, became prominent. The case highlights the complex interplay between scientific innovation, economic development, environmental protection, and social justice.
Mains Hooks
- Governance of Emerging Technologies: Discuss how biosafety and bioethics frameworks are crucial for the responsible governance of rapidly advancing technologies like AI, gene editing, and synthetic biology, ensuring they align with societal values and minimize harm. (Link to Science & Technology, Ethics, Governance).
- Sustainable Development Goals (SDGs): Relate biosafety to SDG 2 (Zero Hunger - GM crops), SDG 3 (Good Health and Well-being - gene therapy), SDG 15 (Life on Land - biodiversity protection from LMOs), and bioethics to ensuring equitable access and benefit sharing (SDG 10 - Reduced Inequalities).
- Innovation vs. Regulation Dilemma: Analyze the tension between fostering scientific innovation for economic growth and human welfare, and the need for stringent regulations to prevent misuse or unforeseen consequences. This is a recurring theme in essays on technology and society.
- Intellectual Property Rights and Traditional Knowledge: Explore the ethical dimensions of IPRs in biotechnology, particularly concerning biopiracy and the protection of traditional knowledge, linking to the National IPR Policy 2016 (as mentioned in reference material) and international agreements like TRIPS and the Nagoya Protocol.
Recent Developments
- CRISPR-based Therapies: Recent approvals and advancements in CRISPR-based gene therapies for diseases like sickle cell anemia and beta-thalassemia have intensified discussions on access, affordability, and the ethical implications of 'curing' genetic conditions. The debate around equitable access to these high-cost therapies is a major bioethical challenge.
- Gene-Edited Organisms: India's regulatory framework for gene-edited plants and animals is evolving. In 2022, the MoEFCC exempted certain gene-edited organisms (SDN-1 and SDN-2 categories, which involve minor changes without foreign DNA) from the stringent GEAC approval process, aiming to streamline research and development. This move sparked debate about balancing regulatory burden with biosafety oversight.
- Synthetic Biology: The rise of synthetic biology, involving the design and construction of new biological parts, devices, and systems, presents novel biosafety and bioethical challenges, requiring new risk assessment paradigms and ethical guidelines for creating entirely novel life forms.
- Data Ethics in Genomics: With large-scale genomic sequencing projects, the ethical challenges of genetic data privacy, consent, data sharing, and potential discrimination based on genetic information are becoming increasingly prominent.
This technique helps prevent mitochondrial diseases in children. It involves moving the nucleus of a fertilized egg into a donor egg that has healthy mitochondria.
This technique helps prevent mitochondrial diseases in children. It involves moving the nucleus of a fertilized egg into a donor egg that has healthy mitochondria. The resulting embryo has DNA from the parents but healthy energy-producing parts from the donor. This is often called 'three-parent baby' technology. It is a form of genetic modification done at the very early embryonic stage to ensure a healthy life.
Guide RNA is a small piece of pre-designed RNA sequence. It works like a GPS for the Cas9 protein. It contains a sequence that is exactly complementary to the target DNA sequence.
Guide RNA is a small piece of pre-designed RNA sequence. It works like a GPS for the Cas9 protein. It contains a sequence that is exactly complementary to the target DNA sequence. Because it binds only to its match, it ensures the 'scissors' do not cut the wrong part of the genome. This high specificity is what makes CRISPR better than previous gene-editing tools. An example is using gRNA to target only the gene responsible for browning in apples.
iPSCs are regular adult cells, like skin cells, that are converted back into a stem cell state in a laboratory. This is done using specific genes. They behave like embryonic stem cells.
iPSCs are regular adult cells, like skin cells, that are converted back into a stem cell state in a laboratory. This is done using specific genes. They behave like embryonic stem cells. This technology is vital because it allows for personalized medicine using a patient's own cells. It also removes the need to use human embryos for research.
Stem cells offer regenerative potential, while biopharmaceuticals, like therapeutic proteins and antibodies, revolutionize medicine, with India a key player in generics and biosimilars.
Definition
Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide to produce more stem cells. They are characterized by two main properties: self-renewal (the ability to go through numerous cycles of cell division while maintaining the undifferentiated state) and potency (the capacity to differentiate into specialized cell types). Stem cells are broadly classified by their origin (embryonic, adult, induced pluripotent) and their potency (totipotent, pluripotent, multipotent, unipotent). Biopharmaceuticals are medicinal products manufactured using biotechnology, often involving recombinant DNA technology. Unlike traditional small-molecule drugs, biopharmaceuticals are large, complex molecules, typically proteins, produced by living organisms or cells. Examples include therapeutic proteins (e.g., insulin, growth hormones), monoclonal antibodies (e.g., for cancer, autoimmune diseases), vaccines, and gene therapies. These drugs interact with specific biological targets, offering high specificity and often fewer side effects than conventional drugs.
Key Facts
- Types of Stem Cells:
- Embryonic Stem Cells (ESCs): Pluripotent, derived from the inner cell mass of a blastocyst.
- Adult Stem Cells (ASCs): Multipotent, found in various tissues (e.g., bone marrow, fat, blood).
- Induced Pluripotent Stem Cells (iPSCs): Pluripotent, reprogrammed from adult somatic cells.
- Mesenchymal Stem Cells (MSCs): A type of ASC, multipotent, found in bone marrow, adipose tissue, etc., with immunomodulatory properties.
- Applications of Stem Cells: Regenerative medicine (tissue repair, organ regeneration), disease modeling, drug discovery, gene therapy.
- Types of Biopharmaceuticals:
- Therapeutic Proteins: Insulin, erythropoietin, growth hormones.
- Monoclonal Antibodies (mAbs): Used in oncology, immunology (e.g., Trastuzumab, Adalimumab).
- Vaccines: Recombinant vaccines, mRNA vaccines.
- Gene and Cell Therapies: CAR T-cell therapy.
- India's Biopharmaceutical Landscape: India is the world’s third-largest pharmaceutical industry by volume and a global leader in low-cost vaccine supply, meeting approximately 20% of global generics demand, with exports to 191 countries in FY25. The sector’s annual turnover reached ₹4.72 lakh crore in FY25, with exports growing at a CAGR of 7% over the last decade (FY15-FY25) (Economic Survey 2025-26, Chart VIII.17). India is shifting from a volume-driven to a value-driven approach, emphasizing complex generics, biosimilars, and innovation (Economic Survey 2025-26, Box VIII.3).
Mechanism/Framework
Stem Cell Function: Stem cells maintain their undifferentiated state through specific molecular pathways. Upon receiving appropriate signals (e.g., growth factors, cytokines, mechanical cues), they undergo differentiation, a process where they commit to a specific cell lineage and acquire specialized functions. This involves changes in gene expression, leading to the formation of various cell types like neurons, muscle cells, or blood cells. Biopharmaceutical Production: The core mechanism for biopharmaceutical production often involves recombinant DNA technology. A gene encoding a therapeutic protein (e.g., human insulin) is isolated and inserted into a vector (e.g., plasmid). This recombinant vector is then introduced into host cells (e.g., bacteria, yeast, mammalian cells like CHO cells). These host cells are cultured in bioreactors, where they express the gene and produce large quantities of the desired protein. The protein is then harvested, purified, and formulated into a drug. This process ensures high purity and consistency of the therapeutic product.
Exam Angle
For Prelims, focus on definitions, types of stem cells and biopharmaceuticals, their key applications, and India's position in the global biopharma market. Questions might test the difference between various stem cell potencies or examples of biopharmaceutical drugs. For Mains, the topic requires analytical depth. Essays or GS-III questions can cover ethical dimensions of stem cell research, regulatory challenges, economic potential, the role of government policies (e.g., PLI schemes for Bulk Drugs, Economic Survey 2025-26, Box VIII.3), R&D investment, and the intersection of biotechnology with healthcare access and affordability. Cross-topic linkages to GS-II (governance, health policy), GS-III (economy, S&T, IPR), and GS-IV (ethics) are crucial.
scitech-diagram-Biopharmaceutical Production Process
scitech-diagram-Stem Cell Potency Hierarchy
Analysis
The convergence of stem cell research and biopharmaceutical development represents a frontier in modern medicine, promising revolutionary treatments for previously incurable diseases. Stem Cell Engineering: Beyond basic research, stem cell engineering involves manipulating stem cells to enhance their therapeutic potential. This includes genetic modification using tools like CRISPR-Cas9 to correct disease-causing mutations in patient-derived iPSCs, which can then be differentiated into healthy cells for transplantation. The development of organoids – 3D tissue cultures derived from stem cells – offers unprecedented opportunities for disease modeling, drug screening, and personalized medicine, reducing reliance on animal testing. However, the field faces significant challenges, including ensuring the safety and efficacy of cell-based therapies, preventing tumor formation from undifferentiated cells, and overcoming immune rejection. Ethical considerations, particularly concerning embryonic stem cells, necessitate robust regulatory frameworks and public discourse. India's regulatory bodies, like the Indian Council of Medical Research (ICMR), have issued guidelines for stem cell research and therapy to ensure ethical conduct and patient safety. Biopharmaceuticals Landscape: The global biopharmaceutical market is expanding rapidly, driven by an aging population, rising incidence of chronic diseases, and advancements in biotechnology. These drugs, including therapeutic proteins, monoclonal antibodies, and gene therapies, offer targeted action and often superior efficacy compared to conventional small-molecule drugs. India has emerged as a significant player, particularly in the production of biosimilars and vaccines. Biosimilars, which are highly similar versions of approved biopharmaceuticals, offer a cost-effective alternative, improving accessibility to expensive treatments. India's strength in generics and vaccines, as highlighted by the Economic Survey 2025-26, where it accounts for 20% of global generics demand and is a global leader in low-cost vaccine supply, provides a strong foundation for further growth in complex biopharmaceuticals. The government's focus on "structural transformation and global integration" and initiatives like the Production Linked Incentive (PLI) scheme for Bulk Drugs (mobilizing investments worth ₹4,763 crore as of September 2025 for 26 critical products, including fermentation-based KSMs like Penicillin G Potassium) are crucial for reducing import dependence and moving up the value chain towards innovation and value-driven approaches (Economic Survey 2025-26, Box VIII.3). However, challenges remain, including high R&D costs, complex manufacturing processes requiring advanced infrastructure and skilled workforce, cold chain logistics, and intellectual property rights (IPR) issues. Industry-academia integration, as advocated by the NEP (Economic Survey 2025-26, Box XI.5), is vital for fostering innovation and developing a skilled talent pool.
Comparison Table
| Feature | Traditional Small-Molecule Drugs | Biopharmaceuticals |
|---|---|---|
| Structure | Simple, well-defined chemical structure, typically 100-1000 Da | Complex, large molecules (proteins, nucleic acids), 10,000-150,000 Da |
| Production | Chemical synthesis | Produced by living cells/organisms (recombinant DNA technology) |
| Specificity | Less specific, can interact with multiple targets | Highly specific, target particular biological pathways or molecules |
| Immunogenicity | Low | Higher potential for immune response (body may recognize as foreign) |
| Stability | Generally stable, oral administration often possible | Less stable, sensitive to temperature/pH, often injectable |
| Cost | Generally lower development and production costs | High R&D and manufacturing costs, leading to higher prices |
| Examples | Aspirin, Paracetamol, Statins | Insulin, Monoclonal Antibodies (e.g., Rituximab), Vaccines |
Case Study
CAR T-cell Therapy: Chimeric Antigen Receptor (CAR) T-cell therapy is a groundbreaking biopharmaceutical approach that exemplifies the synergy between genetic engineering and cell-based therapies. It involves extracting a patient's T-cells, genetically modifying them in the lab to express a CAR that specifically targets cancer cells, and then infusing these engineered CAR T-cells back into the patient. These modified T-cells can then identify and destroy cancer cells. This personalized therapy has shown remarkable success in treating certain blood cancers, such as refractory B-cell acute lymphoblastic leukemia and large B-cell lymphoma, where conventional treatments have failed. The first CAR T-cell therapies, such as Kymriah (Tisagenlecleucel) and Yescarta (Axicabtagene Ciloleucel), received FDA approval in 2017. While highly effective, the therapy is extremely complex, expensive, and can have severe side effects, including cytokine release syndrome and neurotoxicity, requiring specialized medical management. India is also making strides, with institutions like IIT Bombay and Tata Memorial Centre developing indigenous CAR T-cell therapies, aiming to make them more affordable and accessible.
Mains Hooks
- Ethical Dilemmas (GS-IV Ethics): The use of embryonic stem cells, gene editing in germline cells, and the high cost of advanced biopharmaceuticals raise significant ethical questions concerning human dignity, equity, and access to healthcare.
- Regulatory Framework & Governance (GS-II Polity/Governance): Developing robust, agile, and ethical regulatory frameworks for novel cell and gene therapies and biopharmaceuticals is crucial. This includes ensuring patient safety, managing clinical trials, and addressing intellectual property rights (IPR) challenges in a globalized market.
- Economic Potential & R&D (GS-III Economy/S&T): The biopharmaceutical sector is a high-growth industry with immense potential for economic contribution, job creation, and export revenue. Investing in R&D, fostering innovation through industry-academia linkages (Economic Survey 2025-26, Box XI.5), and supporting startups are vital for India to transition from a generics hub to an innovation-driven biopharma leader. CSIR's work in applied innovation, including gene editing platforms and targeted drug delivery for cancer, reflects this shift (Economic Survey 2025-26).
- Healthcare Access & Affordability (GS-II Social Justice): The high cost of biopharmaceuticals and advanced cell therapies poses a significant barrier to access, particularly in developing countries. Strategies like biosimilar development, indigenous production, and public-private partnerships are essential to ensure these life-saving treatments reach a wider population.
- Technological Sovereignty & Self-Reliance (GS-III S&T): Developing indigenous capabilities in stem cell research, biopharmaceutical manufacturing, and advanced medical technologies (e.g., MRI and CT scanners, cardiac stents, as mentioned in Economic Survey 2025-26 for medical devices) is critical for national health security and reducing import dependence, aligning with the 'Atmanirbhar Bharat' vision.
Recent Developments
- CRISPR-based Therapies: In late 2023, the first CRISPR-based gene-editing therapy, Casgevy (exagamglogene autotemcel), was approved in the UK and US for sickle cell disease and beta-thalassemia, marking a significant milestone in gene therapy. This treatment involves editing a patient's own hematopoietic stem cells.
- mRNA Vaccines beyond COVID-19: Building on the success of COVID-19 mRNA vaccines, research is rapidly progressing on mRNA vaccines for other infectious diseases (e.g., influenza, RSV, HIV, malaria) and even for cancer immunotherapy.
- Organoids and Disease Modeling: Advances in organoid technology are allowing scientists to grow "mini-organs" (e.g., brain organoids, gut organoids) from iPSCs, providing more accurate models for studying human diseases, drug toxicity, and personalized medicine approaches.
- Indian Initiatives: India is actively promoting biopharmaceutical R&D and manufacturing. The Department of Pharmaceuticals' PLI scheme for Bulk Drugs (Economic Survey 2025-26, Box VIII.3) aims to boost domestic manufacturing of critical APIs and KSMs, including fermentation-based products essential for biopharma. Furthermore, several Indian companies are investing in biosimilar development and advanced vaccine technologies, aiming to cater to both domestic and international markets. The shift towards value-driven approaches and innovation is a key policy thrust.
This is the process by which the instructions in DNA are converted into a functional product like a protein. It involves two main steps: Transcription and Translation. In Transcription, DNA is copied into mRNA.
This is the process by which the instructions in DNA are converted into a functional product like a protein. It involves two main steps: Transcription and Translation. In Transcription, DNA is copied into mRNA. In Translation, the cell uses that mRNA to build a specific protein. For example, insulin is a protein produced in our body following this exact sequence of events.
This is the process of collecting and storing stem cells from the umbilical cord and placenta after a baby is born. These cells are rich in blood-forming stem cells.
This is the process of collecting and storing stem cells from the umbilical cord and placenta after a baby is born. These cells are rich in blood-forming stem cells. They can be frozen and used later to treat the child or a family member for diseases like anemia or certain cancers. It is like a biological insurance policy for the future.
Somatic editing happens in non-reproductive cells like skin or blood cells. These changes stay with the individual and are not passed to their children. Germline editing happens in eggs, sperm, or embryos.
Somatic editing happens in non-reproductive cells like skin or blood cells. These changes stay with the individual and are not passed to their children. Germline editing happens in eggs, sperm, or embryos. These changes are permanent and will be inherited by all future generations. Most countries, including India, have strict bans or regulations on human germline editing due to ethical risks. An example of somatic editing is treating a patient's lung cancer cells directly.
While the Genome is the complete set of DNA, the Transcriptome is the complete set of all RNA molecules in a cell. It shows us which genes are actually active at a specific time.
While the Genome is the complete set of DNA, the Transcriptome is the complete set of all RNA molecules in a cell. It shows us which genes are actually active at a specific time. For example, a skin cell and a heart cell have the same DNA (Genome), but they have different Transcriptomes because they perform different functions.
CRISPR-Cas9 is a revolutionary tool for editing genes. CRISPR acts as a guide that finds a specific location in the DNA. Cas9 is an enzyme that acts as a pair of scissors to cut the DNA at that exact spot.
CRISPR-Cas9 is a revolutionary tool for editing genes. CRISPR acts as a guide that finds a specific location in the DNA. Cas9 is an enzyme that acts as a pair of scissors to cut the DNA at that exact spot. Once cut, the cell tries to repair the DNA, allowing scientists to add or delete genes. It is much cheaper and faster than older genetic engineering methods.
This is DNA formed by combining genetic material from two different sources. Scientists take a gene from one species and insert it into another. For example, the human insulin gene is put into bacteria.
This is DNA formed by combining genetic material from two different sources. Scientists take a gene from one species and insert it into another. For example, the human insulin gene is put into bacteria. The bacteria then act as tiny factories to produce human insulin for diabetic patients. This process requires enzymes to cut and paste the DNA segments accurately. It is the foundation of modern biotechnology.
These are short pieces of DNA where a specific sequence of nucleotides is repeated many times (e.g., GATA-GATA-GATA). Because these patterns are unique to individuals and species, they act like a 'genetic barcode.
These are short pieces of DNA where a specific sequence of nucleotides is repeated many times (e.g., GATA-GATA-GATA). Because these patterns are unique to individuals and species, they act like a 'genetic barcode.' They are widely used in forensic science to identify individuals and in biology to study the evolutionary history of animals.
Potency refers to the ability of a stem cell to turn into different cell types. Totipotent cells can form everything, including the placenta. Pluripotent cells can form all body cells but not the placenta.
Potency refers to the ability of a stem cell to turn into different cell types. Totipotent cells can form everything, including the placenta. Pluripotent cells can form all body cells but not the placenta. Multipotent cells can only form a specific family of cells, like blood or skin. For example, a blood stem cell cannot become a brain cell.
Cas9 is a specialized enzyme that acts as the physical 'scissors' in the CRISPR system. Its job is to cut the double-stranded DNA at a specific location. It is guided to this location by a piece of RNA.
Cas9 is a specialized enzyme that acts as the physical 'scissors' in the CRISPR system. Its job is to cut the double-stranded DNA at a specific location. It is guided to this location by a piece of RNA. Once the cut is made, the cell's natural repair machinery takes over. This allows scientists to deactivate a harmful gene. For example, in cancer research, Cas9 can be used to cut the DNA of cancer cells to stop them from growing.
Ready to practice? Start an interactive lesson.
Start Lesson: Biosafety & Bioethics